Yildiz Pekoz, A. Et Al. 2022. Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis. DRUG DELIVERY , vol.29, no.1 , 2846-2854.

Yildiz Pekoz, A., Akbal Dagistan, O., Fael, H., Culha, M., Erturk, A., Basarir, N. S., ... Sahin, G.(2022). Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis. DRUG DELIVERY , vol.29, no.1, 2846-2854.

Yildiz Pekoz, Ayca Et Al. "Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis," DRUG DELIVERY , vol.29, no.1, 2846-2854, 2022

Yildiz Pekoz, Ayca Y. Et Al. "Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis." DRUG DELIVERY , vol.29, no.1, pp.2846-2854, 2022

Yildiz Pekoz, A. Et Al. (2022) . "Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis." DRUG DELIVERY , vol.29, no.1, pp.2846-2854.

@article{article, author={Ayca Yildiz Pekoz Et Al. }, title={Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis}, journal={DRUG DELIVERY}, year=2022, pages={2846-2854} }